Ariad Pharmaceuticals (NASDAQ: ARIA) gained approval from the Food and Drug Administration for its chronic myeloid leukemia drug Iclusig in mid-December. The drug is currently approved for patients who don't respond to treatment with Novartis' (NVS 4.45%) Gleevec, Tasigna, or Bristol-Myers Squibb's (BMY 1.16%) Sprycel. With FDA approval now complete, the big question mark hanging over Ariad in 2013 is whether its Iclusig launch will be successful. In this video, analyst Max Macaluso weighs in and highlights issues that investors need to watch this year.
Will Iclusig's drug launch be a success?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo